mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for IL2RB
Gene summary
Basic gene Info.Gene symbolIL2RB
Gene nameinterleukin 2 receptor, beta
CytomapUCSC genome browser: 22q13.1
Type of geneprotein-coding
DescriptionCD122 antigenIL-2 receptor subunit betaIL-2R subunit betaIL-2RBhigh affinity IL-2 receptor beta subunithigh affinity IL-2 receptor subunit betainterleukin 15 receptor, betainterleukin-2 receptor subunit betap75
Modification date20141207
dbXrefs MIM : 146710
Ensembl : ENSG00000100385
HPRD : 00896
Vega : OTTHUMG00000150534
ProteinUniProt: P14784
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_IL2RB
BioGPS: 3560
PathwayNCI Pathway Interaction Database: IL2RB
Pathway Commons: IL2RB
ContextiHOP: IL2RB
ligand binding site mutation search in PubMed: IL2RB
UCL Cancer Institute: IL2RB
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:0019221cytokine-mediated signaling pathway7736574
GO:0038110interleukin-2-mediated signaling pathway7736574
GO:0043066negative regulation of apoptotic process7736574

Ligand binding site mutations for IL2RB
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for IL2RB
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for IL2RB from PDB

Differential gene expression and gene-gene network for IL2RB
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of IL2RB and the right PPI network was created from samples without mutations in the LBS of IL2RB. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for IL2RB
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C0003873Arthritis, Rheumatoid10Biomarker, GeneticVariation

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for IL2RB
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
Approved|investigationalDB00004Denileukin diftitoxBiotech

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of IL2RB go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of IL2RB
Multiple alignments for P14784 in multiple species
LBSAA sequence# speciesSpecies
F37SQFTCFYNSRA2Homo sapiens, Pan troglodytes
F37SHLECFYNSRA1Mus musculus
F37SHLKCFYNSRA1Rattus norvegicus
H62TSCQVHAWPDR2Homo sapiens, Pan troglodytes
H62TTCHVHAKSNL1Mus musculus
H62TSCHIHAKSDM1Rattus norvegicus
L132FENLRLMAPIS2Homo sapiens, Pan troglodytes
L132FDNLRLVAPHS1Mus musculus
L132FDNLRLIAPHS1Rattus norvegicus
M133ENLRLMAPISL2Homo sapiens, Pan troglodytes
M133DNLRLVAPHSL1Mus musculus
M133DNLRLIAPHSL1Rattus norvegicus
N39FTCFYNSRANI2Homo sapiens, Pan troglodytes
N39LECFYNSRANV1Mus musculus
N39LKCFYNSRANV1Rattus norvegicus
P222FTTWSPWSQPL2Homo sapiens, Pan troglodytes
P222TGTWSPWSQPL1Mus musculus
P222TRTWSPWSQPM1Rattus norvegicus
R107DIVTLRVLCRE2Homo sapiens, Pan troglodytes
R107DLLDINVVCWE1Mus musculus
R107DLLSLSVVCWE1Rattus norvegicus
R131PFENLRLMAPI2Homo sapiens, Pan troglodytes
R131PFDNLRLVAPH1Mus musculus
R131PFDNLRLIAPH1Rattus norvegicus
S45SRANISCVWSQ2Homo sapiens, Pan troglodytes
S45SRANVSCMWSH1Mus musculus
S45SRANVSCMWSP1Rattus norvegicus
W116REGVRWRVMAI2Homo sapiens, Pan troglodytes
W116WEEKGWRRVKT2Mus musculus, Rattus norvegicus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas